“The question of resistance is paramount in terms of treating human populations – there will be a plethora of drugs on the market sooner or later, and I’m sure we will see drug resistance mutations rather soon,” Avi said.
One of the mutations found by researchers could prove significant in terms of drug resistance. The mutation C-14408-T is found in the RdRP enzyme that is in charge of copying the viral gene. Because the gene’s coded mechanisms are susceptible to Remdevisir that has already been approved for use in Estonia and Favipiravir, samples of which should soon be arriving from Japan to be used in medical trials in Estonia, mutations of the gene could have unwanted side-effects.
“Therefore, it would be absolutely necessary to sequence the patient’s virus before prescribing Remdesivir or Favipiravir treatment,” authors of the study write.
Risks need to be contained
Analyzing viral genomes makes it possible to estimate the pathogen’s directions of travel and take appropriate scientific measures when responding to new waves of infection.
After the initial pilot study, researchers want to sequence further genomes that could shed light on the virus reaching Estonia and its spread here. The long-term goal is to have a systematic approach for future epidemics.